J. Kwakman

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study

H. Sorbye, M. Bärlund, P. Flygare, 2022, ESMO open.

Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer.

C. Punt, L. Mol, J.J. Kwakman, 2022, Clinical colorectal cancer.

Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group

C. Punt, M. Koopman, E. van Werkhoven, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients

C. Punt, J. Pruijt, H. Boot, 2017, Acta oncologica.

Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study).

H. Sorbye, P. Flygare, B. Glimelius, 2024, Acta oncologica.

Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients

C. Punt, J. Pruijt, H. Boot, 2017, Acta oncologica.